Related Experiment Video
Updated: Apr 28, 2026

Development of Cell-type specific anti-HIV gp120 aptamers for siRNA delivery
Published on: June 23, 2011
Anti-MPER antibodies with heterogeneous neutralization capacity are detectable in most untreated HIV-1 infected
Luis M Molinos-Albert, Jorge Carrillo, Marta Curriu
1IrsiCaixa-HIVACAT, Institut de Recerca en Ciències de la Salut Germans Trias i Pujol (IGTP), Hospital Germans Trias i Pujol, UAB, Badalona, 08916 Barcelona, Catalonia, Spain. jblanco@irsicaixa.es.
Background:
The MPER region of the HIV-1 envelope glycoprotein gp41 is targeted by broadly neutralizing antibodies. However, the localization of this epitope in a hydrophobic environment seems to hamper the elicitation of these antibodies in HIV infected individuals.We have quantified and characterized anti-MPER antibodies by ELISA and by flow cytometry using a collection of mini gp41-derived proteins expressed on the surface of 293T cells. Longitudinal plasma samples from 35 HIV-1 infected individuals were assayed for MPER recognition and MPER-dependent neutralizing capacity using HIV-2 viruses engrafted with HIV-1 MPER sequences.
Results:
Miniproteins devoid of the cysteine loop of gp41 exposed the MPER on 293T cell membrane. Anti-MPER antibodies were identified in most individuals and were stable when analyzed in longitudinal samples. The magnitude of the responses was strongly correlated with the global response to the HIV-1 envelope glycoprotein, suggesting no specific limitation for anti-MPER antibodies. Peptide mapping showed poor recognition of the C-terminal MPER moiety and a wide presence of antibodies against the 2F5 epitope. However, antibody titers failed to correlate with 2F5-blocking activity and, more importantly, with the specific neutralization of HIV-2 chimeric viruses bearing the HIV-1 MPER sequence; suggesting a strong functional heterogeneity in anti-MPER humoral responses.
Conclusions:
Anti-MPER antibodies can be detected in the vast majority of HIV-1 infected individuals and are generated in the context of the global anti-Env response. However, the neutralizing capacity is heterogeneous suggesting that eliciting neutralizing anti-MPER antibodies by immunization might require refinement of immunogens to skip nonneutralizing responses.
Insights
Broadly neutralizing antibodies targeting the MPER region of HIV-1 gp41 are present in most infected individuals. However, their neutralizing capacity varies significantly, indicating a need for refined immunogen design for effective vaccine development.
Area of Science:
- Immunology
- Virology
- Vaccine Development
Background:
- The Membrane Proximal External Region (MPER) of HIV-1 gp41 is a key target for broadly neutralizing antibodies.
- The hydrophobic nature of the MPER epitope may hinder antibody elicitation in infected individuals.
Purpose of the Study:
- To quantify and characterize anti-MPER antibodies in HIV-1 infected individuals.
- To assess the neutralizing capacity of anti-MPER antibodies against MPER-grafted viruses.
Main Methods:
- ELISA and flow cytometry using gp41-derived miniproteins on 293T cells.
- Analysis of longitudinal plasma samples from 35 HIV-1 infected individuals.
- Assay of MPER recognition and neutralization using HIV-2 viruses with HIV-1 MPER sequences.
Main Results:
- Anti-MPER antibodies were detected in most individuals and were stable over time.
- Antibody response magnitude correlated with the overall anti-HIV-1 envelope response.
- Significant functional heterogeneity was observed, with antibody titers not correlating with neutralization capacity.
Conclusions:
- Anti-MPER antibodies are common in HIV-1 infected individuals within the broader anti-Env response.
- The heterogeneous neutralizing capacity suggests current immunogens may elicit non-neutralizing responses.
- Refined immunogen strategies are necessary to elicit potent neutralizing anti-MPER antibodies for vaccine development.
More Related Videos
14:23A Restriction Enzyme Based Cloning Method to Assess the In vitro Replication Capacity of HIV-1 Subtype C Gag-MJ4 Chimeric Viruses
Published on: August 31, 2014
07:10Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay
Published on: September 14, 2014